Immune Checkpoint Inhibitors for Patients with Advanced Non-Small Cell Lung Cancer: A Systematic Review

Abstract Introduction Second-line treatment options are limited for patients with advanced non-small cell lung cancer (NSCLC). Standard therapy includes cytotoxic agents, docetaxel and pemetrexed, and the epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs), erlotinib and gefiti...

Full description

Saved in:
Bibliographic Details
Published in:Clinical lung cancer 2017-09, Vol.18 (5), p.444-459.e1
Main Authors: Ellis, Peter M., MBBS, PhD, Vella, Emily T., PhD, Ung, Yee C., MD
Format: Article
Language:English
Subjects:
Antibodies, Monoclonal - therapeutic use
Antibodies, Monoclonal, Humanized - therapeutic use
Antineoplastic Agents, Immunological - therapeutic use
Antineoplastic Combined Chemotherapy Protocols - therapeutic use
Atezolizumab
B7-H1 Antigen - antagonists & inhibitors
Carcinoma, Non-Small-Cell Lung - drug therapy
Carcinoma, Non-Small-Cell Lung - secondary
Chemotherapy
Docetaxel
Hematology, Oncology and Palliative Medicine
Humans
Lung Neoplasms - drug therapy
Lung Neoplasms - pathology
Neoplasm Staging
Nivolumab
Pembrolizumab
Programmed Cell Death 1 Receptor - antagonists & inhibitors
Pulmonary/Respiratory
Randomized Controlled Trials as Topic
Survival Rate
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Abstract Introduction Second-line treatment options are limited for patients with advanced non-small cell lung cancer (NSCLC). Standard therapy includes cytotoxic agents, docetaxel and pemetrexed, and the epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs), erlotinib and gefitinib. Immune checkpoint inhibitors are a new class of treatment that have shown durable overall radiological response rates and have been well tolerated. The objective of this systematic review was to investigate the efficacy of immune checkpoint inhibitors compared with other chemotherapies in patients with advanced NSCLC. Methods MEDLINE, EMBASE, and PubMed were searched for randomized controlled trials (RCTs) comparing treatment with immune checkpoint inhibitors against treatment with chemotherapy in patients with stage IIIB or IV NSCLC. Results Nine RCTs with 15 publications were included. A significant overall survival benefit of second-line nivolumab (non-squamous: HR 0.72, 95% CI, 0.60-0.77; p
ISSN:1525-7304
1938-0690
DOI:10.1016/j.cllc.2017.02.001